Thermo Fisher Scientific Inc (TMO) Financials
TMO Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 98.7 billion | 51.9 billion |
| 2023-09-30 | 97.1 billion | 51.6 billion |
| 2023-06-30 | 94.1 billion | 50.2 billion |
| 2023-03-31 | 94.7 billion | 52.2 billion |
TMO Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | 3.3 billion | 61.0 million |
| 2023-09-30 | 2.1 billion | -150.0 million |
| 2023-06-30 | 1.3 billion | -76.0 million |
| 2023-03-31 | 271.0 million | 76.0 million |
TMO Net Income
| Date | Net Income |
|---|---|
| 2023-12-31 | 1.6 billion |
| 2023-09-30 | 1.7 billion |
| 2023-06-30 | 1.4 billion |
| 2023-03-31 | 1.3 billion |
TMO Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 8.1 billion | - | - |
| 2023-09-30 | 6.2 billion | 30.5 billion | - |
| 2023-06-30 | 3.1 billion | 29.2 billion | - |
| 2023-03-31 | 3.5 billion | 29.1 billion | - |
TMO Shares Outstanding
TMO Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 405.0 million | 327.0 million | 2.1 billion | - |
| 2023-09-30 | 332.0 million | 319.0 million | 1.6 billion | - |
| 2023-06-30 | 284.0 million | 345.0 million | 1.7 billion | - |
| 2023-03-31 | 458.0 million | 346.0 million | 1.6 billion | - |
TMO Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 10.9 billion | 6.4 billion |
| 2023-09-30 | 10.6 billion | 6.1 billion |
| 2023-06-30 | 10.7 billion | 6.3 billion |
| 2023-03-31 | 10.7 billion | 6.4 billion |
TMO
List: Challengers
Price: $571.73
Dividend Yield: 0.00%
Forward Dividend Yield: 0.27%
Payout Ratio: 10.21%
Dividend Per Share: 1.56 USD
Earnings Per Share: 15.43 USD
P/E Ratio: 35.82
Exchange: NYQ
Sector: Healthcare
Industry: Diagnostics & Research
Volume: 1.2 million
Ebitda: 1.6 billionMarket Capitalization: 215.8 billion
Average Dividend Frequency: 4
Years Paying Dividends: 13
DGR3: 16.53%
DGR5: 15.07%
DGR10: 8.58%